These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24557576)

  • 1. Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era.
    Salgia RJ; Goodrich NP; Simpson H; Merion RM; Sharma P
    Dig Dis Sci; 2014 Aug; 59(8):1976-82. PubMed ID: 24557576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Post-Liver Transplantation Outcomes in Portopulmonary Hypertension and Pulmonary Venous Hypertension: A Single-Center Experience.
    Rajaram P; Parekh A; Fisher M; Kempker J; Subramanian R
    Transplant Proc; 2017 Mar; 49(2):338-343. PubMed ID: 28219595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception.
    DuBrock HM; Del Valle KT; Krowka MJ
    Liver Transpl; 2022 Jul; 28(7):1224-1230. PubMed ID: 35106916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.
    Jose A; Shah SA; Anwar N; Jones CR; Sherman KE; Elwing JM
    Liver Transpl; 2021 Dec; 27(12):1811-1823. PubMed ID: 33964116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portopulmonary hypertension: Still an appropriate consideration for liver transplantation?
    Verma S; Hand F; Armstrong MJ; de Vos M; Thorburn D; Pan T; Klinck J; Westbrook RH; Auzinger G; Bathgate A; Masson S; Holt A; Houlihan DD; Ferguson JW
    Liver Transpl; 2016 Dec; 22(12):1637-1642. PubMed ID: 27593213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
    DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
    Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation.
    Raza MH; Kwon Y; Kobierski P; Misra AC; Lim A; Goldbeck C; Etesami K; Kohli R; Emamaullee J
    Liver Transpl; 2023 Feb; 29(2):134-144. PubMed ID: 35876731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward.
    Krowka MJ; Wiesner RH; Heimbach JK
    J Hepatol; 2013 Aug; 59(2):367-74. PubMed ID: 23557870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Transplantation for Hepatitis B in Early Adulthood: Analysis of the United Network for Organ Sharing Database.
    Rifai G; Anani A; Hanouneh IA; Mohamad B; Matloob A; Lopez R; Zein NN; Alkhouri N
    Transplant Proc; 2016 Dec; 48(10):3362-3367. PubMed ID: 27931582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era.
    Malinis MF; Chen S; Allore HG; Quagliarello VJ
    Ann Transplant; 2014 Sep; 19():478-87. PubMed ID: 25256592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome in liver transplantation candidates with portopulmonary hypertension.
    Savale L; Sattler C; Coilly A; Conti F; Renard S; Francoz C; Bouvaist H; Feray C; Borentain P; Jaïs X; Montani D; Parent F; O'Connell C; Hervé P; Humbert M; Simonneau G; Samuel D; Calmus Y; Duvoux C; Durand F; Duclos-Vallée JC; Sitbon O
    Hepatology; 2017 May; 65(5):1683-1692. PubMed ID: 27997987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Porto-pulmonary hypertension: a comprehensive review".
    Liberal R; Grant CR; Baptista R; Macedo G
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):157-67. PubMed ID: 25659878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma Is Facilitated by Exception Points With Acceptable Long-term Outcomes.
    Brahmbhatt M; Prenner S; Bittermann T
    Transplantation; 2020 Jun; 104(6):1187-1192. PubMed ID: 31577674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portopulmonary hypertension in the current era of pulmonary hypertension management.
    Savale L; Guimas M; Ebstein N; Fertin M; Jevnikar M; Renard S; Horeau-Langlard D; Tromeur C; Chabanne C; Prevot G; Chaouat A; Moceri P; Artaud-Macari É; Degano B; Tresorier R; Boissin C; Bouvaist H; Simon AC; Riou M; Favrolt N; Palat S; Bourlier D; Magro P; Cottin V; Bergot E; Lamblin N; Jaïs X; Coilly A; Durand F; Francoz C; Conti F; Hervé P; Simonneau G; Montani D; Duclos-Vallée JC; Samuel D; Humbert M; De Groote P; Sitbon O
    J Hepatol; 2020 Jul; 73(1):130-139. PubMed ID: 32145258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension.
    Cartin-Ceba R; Burger C; Swanson K; Vargas H; Aqel B; Keaveny AP; Heimbach J; Taner T; Nyberg S; Rosen C; Cajigas H; DuBrock H; Krowka MJ
    Transplantation; 2021 Oct; 105(10):2283-2290. PubMed ID: 33065725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics.
    Hung K; Gralla J; Dodge JL; Bambha KM; Dirchwolf M; Rosen HR; Biggins SW
    Liver Transpl; 2015 Nov; 21(11):1365-73. PubMed ID: 25865434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of survival in portopulmonary hypertension: a 20-year experience.
    Aggarwal M; Li M; Bhardwaj A; Wallace WD; Wang X; Carey WD; Dweik RA; Heresi GA; Tonelli AR
    Eur J Gastroenterol Hepatol; 2022 Apr; 34(4):449-456. PubMed ID: 34907982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MELD exceptions for portopulmonary hypertension: current policy and future implementation.
    Goldberg DS; Batra S; Sahay S; Kawut SM; Fallon MB
    Am J Transplant; 2014 Sep; 14(9):2081-7. PubMed ID: 24984921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MELD score measured day 10 after orthotopic liver transplantation predicts death and re-transplantation within the first year.
    Rostved AA; Lundgren JD; Hillingsø J; Peters L; Mocroft A; Rasmussen A
    Scand J Gastroenterol; 2016 Nov; 51(11):1360-6. PubMed ID: 27319374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.